Lupin
Lupin receives USFDA approval for Sevelamer Hydrochloride tablets
Mumbai/UNI: Pharma major Lupin on Thursday said that it has received approval for its Sevelamer Hydrochloride Tablets, 400 mg and 800 mg from the United States Food and Drug Administration (USFDA) to market a generic equivalent of Renagel Tablets, 400 mg, and 800 mg of Genzyme Corporation.
The product will be manufactured at Lupin's facility in Nagpur, India.
Sevelamer Hydrochloride Tablets are indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis.
Sevelamer Hydrochloride Tablets had an estimated annual sales of USD 80 million in the US (IQVIA MAT March 2021).
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
